Clinical trial · Interventional
Phase 2 Study of TLK286 in Metastatic Breast Cancer
NCT00035841CI-TRIAL-00005267completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TLK286 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic diagnosis of breast cancer * Metastatic disease * Measurable or evaluable disease * No prior chemotherapy regimens * Age at least 18 years * Adequate liver and kidney function * Adequate bone marrow function Exclusion Criteria: * Pregnant or lactating women * Unstable medical conditions * Chemotherapy within 14 days of TLK286 * Radiation therapy within 14 days of TLK286 * Hormonal therapy within 14 days of TLK286 * Immunotherapy within 14 days of TLK286 * CNS metastasis unless controlled by treatment
References
Publications (0)
Data not yet available
No reference posted for this study.